The relationship between the expression of p27Kip1, p53 and the infiltration, metastasis and prognosis in gastric carcinoma

Chinese-German Journal of Clinical Oncology

Volumn 4, Issue 3, 2005, Pages 155-160

  Chen, Li ^a   Lu, Peng ^a   Song, Hongjie ^b   Li, Dechun ^c  

^a NANTONG UNIVERSITY   (China)

^b Department of Pathology   (China)

^c SuZhou University   (China)

Author keywords

Gastric carcinoma; p27Kip1gene; p53gene; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

EID: 22144453953     PISSN: 16101979     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10330-004-0273-5     Document Type: Article

References (25)

1. Kip1 and cyclin E correlates with survival in gastric carcinoma patients. J Surg Res, 2000, 94: 56-60.
2. Gurel S, Dolar E, Yerci O, et al. Expression of p53 protein and prognosis in gastric carcinoma. J Int Med Res, 1999, 27: 85-89.
3. Hollstein M, Sidransky D, Vogelstein B, et al. P53 mutations in human cancers. Science, 1991, 335: 675-679.
4. Tamura G, Kihana T, Nomura K, et al. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res, 1991, 51: 3056-3058.
5. Sobin LH, Wittekind CH. TNM classification of malignant tumours, 5th edn. Geneva: International Union Against Cancer. 1997. 59-62.
6. Kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst, 1998, 90: 1284-1291.
7. Kip1, p21Waf1/Cip1 and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology, 2001, 39: 603-610.
8. Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21(waf1/cipl/sdil), but not p53 protein, is a factor in the survial of patients with advanced gastric carcinoma. Cancer, 1997, 79: 2067-2072.
9. Kaku T, Kamura T, Kinukawa N, et al. Angiogenesis in endometrial cancinoma. Cancer, 1997, 80: 741-747.
10. Sheer CJ. G1 phase progression: Cycling on cue. Cell, 1994, 79: 551-555.
11. Hunter T, Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell, 1994, 79: 573-582.
12. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracelluar antimitogenic signals. Cell, 1994, 78: 59-67.
13. Puay T, Blake C, Molly W, et al. The cell cycle inhibitor p27 is an independent prognostic, in small (T1a, b) invasive breast carcinomas. Cancer Res, 1997, 57: 1259-1263.
14. Takano Y, Koto Y, Diest PJ, et al. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol, 2000, 156: 585-594.
15. Kip1 and apoptosis in tumour cells on the overall survival of patients with non-early stage gastric carcinoma. Cancer, 1999, 85: 1711-1717.
16. Erlanson M, Portin C, Linderholm B, et al. Expression of cyclin E and the cyclin-dependent kinase inhabitor p27 in malignant lymphomas-prognostic implications. Blood, 1998, 57: 770-777.
17. Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer, 2000, 89: 2247-2257.
18. Kip1 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology, 2000, 36: 245-251.
19. Starzynska T, Bromley M, Ghosh A, et al. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer, 1992, 66: 558-562.
20. Casson AG, Tammemagi M, Eskandarian S, et al. P53 alterations in esophageal cancer: Association with clinicopathological features, risk factors, and survival. Mod Pathol, 1998, 51: 71-79.
21. Ishida H, Irie K, Itoh T, et al. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer, 1997, 80: 1034-1045.
22. Sakaguchi T, Watanabe A, Sawada H, et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer, 1998, 82, 1238-1243.
23. Maehara Y, Tomoda M, Hasuda S, et al. Prognostic value of p53 protein expression for patients with gastric cancer - a multivariate analysis. Br J Cancer, 1999, 79: 1255-1261.
24. Kip1 in gastric cancer. Anticancer Res, 2000, 20: 1787-1792.
25. Müller W, Noguchi T, Wirtz HC, et al. Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 Waf1/Cip1 in gastric cancer. J Pathol, 1999, 189: 186-193.